 | • レポートコード：MRC2-11QY11990 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は脆弱X症候群のグローバル市場について調査・分析したレポートです。種類別（ACT-01、AMO-01、ANAVEX-273、AUT-00206、ブリオスタチン-1、カンナビジオール、その他）市場規模、用途別（クリニック、病院、研究センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別脆弱X症候群の競争状況、市場シェア ・世界の脆弱X症候群市場：種類別市場規模 2015年-2020年（ACT-01、AMO-01、ANAVEX-273、AUT-00206、ブリオスタチン-1、カンナビジオール、その他） ・世界の脆弱X症候群市場：種類別市場規模予測 2021年-2026年（ACT-01、AMO-01、ANAVEX-273、AUT-00206、ブリオスタチン-1、カンナビジオール、その他） ・世界の脆弱X症候群市場：用途別市場規模 2015年-2020年（クリニック、病院、研究センター） ・世界の脆弱X症候群市場：用途別市場規模予測 2021年-2026年（クリニック、病院、研究センター） ・北米の脆弱X症候群市場分析：米国、カナダ ・ヨーロッパの脆弱X症候群市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの脆弱X症候群市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の脆弱X症候群市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの脆弱X症候群市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Aelis Farma SAS、Alcobra Ltd、AMO Pharma Limited、Confluence Pharmaceuticals LLC、Eli Lilly and Company、F. Hoffmann-La Roche Ltd.、Marinus Pharmaceuticals, Inc.、MI.TO. Technology S.r.L.、Neuren Pharmaceuticals Limited、Ovid Therapeutics Inc.、Sage Therapeutics, Inc.、Zynerba Pharmaceuticals, Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Fragile X Syndrome Market
The global Fragile X Syndrome market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Fragile X Syndrome Scope and Market Size
Fragile X Syndrome market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Fragile X Syndrome market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Aelis Farma SAS
Alcobra Ltd
AMO Pharma Limited
Confluence Pharmaceuticals LLC
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Marinus Pharmaceuticals, Inc.
MI.TO. Technology S.r.L.
Neuren Pharmaceuticals Limited
Ovid Therapeutics Inc.
Sage Therapeutics, Inc.
Zynerba Pharmaceuticals, Inc.
Market segment by Type, the product can be split into
ACT-01
AMO-01
ANAVEX-273
AUT-00206
Bryostatin-1
Cannabidiol
Others
Market segment by Application, split into
Clinic
Hopital
Research Center
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Fragile X Syndrome Revenue
1.4 Market by Type
1.4.1 Global Fragile X Syndrome Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 ACT-01
1.4.3 AMO-01
1.4.4 ANAVEX-273
1.4.5 AUT-00206
1.4.6 Bryostatin-1
1.4.7 Cannabidiol
1.4.8 Others
1.5 Market by Application
1.5.1 Global Fragile X Syndrome Market Share by Application: 2020 VS 2026
1.5.2 Clinic
1.5.3 Hopital
1.5.4 Research Center
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Fragile X Syndrome Market Perspective (2015-2026)
2.2 Global Fragile X Syndrome Growth Trends by Regions
2.2.1 Fragile X Syndrome Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Fragile X Syndrome Historic Market Share by Regions (2015-2020)
2.2.3 Fragile X Syndrome Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Fragile X Syndrome Market Growth Strategy
2.3.6 Primary Interviews with Key Fragile X Syndrome Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Fragile X Syndrome Players by Market Size
3.1.1 Global Top Fragile X Syndrome Players by Revenue (2015-2020)
3.1.2 Global Fragile X Syndrome Revenue Market Share by Players (2015-2020)
3.1.3 Global Fragile X Syndrome Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Fragile X Syndrome Market Concentration Ratio
3.2.1 Global Fragile X Syndrome Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Fragile X Syndrome Revenue in 2019
3.3 Fragile X Syndrome Key Players Head office and Area Served
3.4 Key Players Fragile X Syndrome Product Solution and Service
3.5 Date of Enter into Fragile X Syndrome Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Fragile X Syndrome Historic Market Size by Type (2015-2020)
4.2 Global Fragile X Syndrome Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Fragile X Syndrome Market Size by Application (2015-2020)
5.2 Global Fragile X Syndrome Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Fragile X Syndrome Market Size (2015-2020)
6.2 Fragile X Syndrome Key Players in North America (2019-2020)
6.3 North America Fragile X Syndrome Market Size by Type (2015-2020)
6.4 North America Fragile X Syndrome Market Size by Application (2015-2020)
7 Europe
7.1 Europe Fragile X Syndrome Market Size (2015-2020)
7.2 Fragile X Syndrome Key Players in Europe (2019-2020)
7.3 Europe Fragile X Syndrome Market Size by Type (2015-2020)
7.4 Europe Fragile X Syndrome Market Size by Application (2015-2020)
8 China
8.1 China Fragile X Syndrome Market Size (2015-2020)
8.2 Fragile X Syndrome Key Players in China (2019-2020)
8.3 China Fragile X Syndrome Market Size by Type (2015-2020)
8.4 China Fragile X Syndrome Market Size by Application (2015-2020)
9 Japan
9.1 Japan Fragile X Syndrome Market Size (2015-2020)
9.2 Fragile X Syndrome Key Players in Japan (2019-2020)
9.3 Japan Fragile X Syndrome Market Size by Type (2015-2020)
9.4 Japan Fragile X Syndrome Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Fragile X Syndrome Market Size (2015-2020)
10.2 Fragile X Syndrome Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Fragile X Syndrome Market Size by Type (2015-2020)
10.4 Southeast Asia Fragile X Syndrome Market Size by Application (2015-2020)
11 India
11.1 India Fragile X Syndrome Market Size (2015-2020)
11.2 Fragile X Syndrome Key Players in India (2019-2020)
11.3 India Fragile X Syndrome Market Size by Type (2015-2020)
11.4 India Fragile X Syndrome Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Fragile X Syndrome Market Size (2015-2020)
12.2 Fragile X Syndrome Key Players in Central & South America (2019-2020)
12.3 Central & South America Fragile X Syndrome Market Size by Type (2015-2020)
12.4 Central & South America Fragile X Syndrome Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Aelis Farma SAS
13.1.1 Aelis Farma SAS Company Details
13.1.2 Aelis Farma SAS Business Overview
13.1.3 Aelis Farma SAS Fragile X Syndrome Introduction
13.1.4 Aelis Farma SAS Revenue in Fragile X Syndrome Business (2015-2020))
13.1.5 Aelis Farma SAS Recent Development
13.2 Alcobra Ltd
13.2.1 Alcobra Ltd Company Details
13.2.2 Alcobra Ltd Business Overview
13.2.3 Alcobra Ltd Fragile X Syndrome Introduction
13.2.4 Alcobra Ltd Revenue in Fragile X Syndrome Business (2015-2020)
13.2.5 Alcobra Ltd Recent Development
13.3 AMO Pharma Limited
13.3.1 AMO Pharma Limited Company Details
13.3.2 AMO Pharma Limited Business Overview
13.3.3 AMO Pharma Limited Fragile X Syndrome Introduction
13.3.4 AMO Pharma Limited Revenue in Fragile X Syndrome Business (2015-2020)
13.3.5 AMO Pharma Limited Recent Development
13.4 Confluence Pharmaceuticals LLC
13.4.1 Confluence Pharmaceuticals LLC Company Details
13.4.2 Confluence Pharmaceuticals LLC Business Overview
13.4.3 Confluence Pharmaceuticals LLC Fragile X Syndrome Introduction
13.4.4 Confluence Pharmaceuticals LLC Revenue in Fragile X Syndrome Business (2015-2020)
13.4.5 Confluence Pharmaceuticals LLC Recent Development
13.5 Eli Lilly and Company
13.5.1 Eli Lilly and Company Company Details
13.5.2 Eli Lilly and Company Business Overview
13.5.3 Eli Lilly and Company Fragile X Syndrome Introduction
13.5.4 Eli Lilly and Company Revenue in Fragile X Syndrome Business (2015-2020)
13.5.5 Eli Lilly and Company Recent Development
13.6 F. Hoffmann-La Roche Ltd.
13.6.1 F. Hoffmann-La Roche Ltd. Company Details
13.6.2 F. Hoffmann-La Roche Ltd. Business Overview
13.6.3 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Introduction
13.6.4 F. Hoffmann-La Roche Ltd. Revenue in Fragile X Syndrome Business (2015-2020)
13.6.5 F. Hoffmann-La Roche Ltd. Recent Development
13.7 Marinus Pharmaceuticals, Inc.
13.7.1 Marinus Pharmaceuticals, Inc. Company Details
13.7.2 Marinus Pharmaceuticals, Inc. Business Overview
13.7.3 Marinus Pharmaceuticals, Inc. Fragile X Syndrome Introduction
13.7.4 Marinus Pharmaceuticals, Inc. Revenue in Fragile X Syndrome Business (2015-2020)
13.7.5 Marinus Pharmaceuticals, Inc. Recent Development
13.8 MI.TO. Technology S.r.L.
13.8.1 MI.TO. Technology S.r.L. Company Details
13.8.2 MI.TO. Technology S.r.L. Business Overview
13.8.3 MI.TO. Technology S.r.L. Fragile X Syndrome Introduction
13.8.4 MI.TO. Technology S.r.L. Revenue in Fragile X Syndrome Business (2015-2020)
13.8.5 MI.TO. Technology S.r.L. Recent Development
13.9 Neuren Pharmaceuticals Limited
13.9.1 Neuren Pharmaceuticals Limited Company Details
13.9.2 Neuren Pharmaceuticals Limited Business Overview
13.9.3 Neuren Pharmaceuticals Limited Fragile X Syndrome Introduction
13.9.4 Neuren Pharmaceuticals Limited Revenue in Fragile X Syndrome Business (2015-2020)
13.9.5 Neuren Pharmaceuticals Limited Recent Development
13.10 Ovid Therapeutics Inc.
13.10.1 Ovid Therapeutics Inc. Company Details
13.10.2 Ovid Therapeutics Inc. Business Overview
13.10.3 Ovid Therapeutics Inc. Fragile X Syndrome Introduction
13.10.4 Ovid Therapeutics Inc. Revenue in Fragile X Syndrome Business (2015-2020)
13.10.5 Ovid Therapeutics Inc. Recent Development
13.11 Sage Therapeutics, Inc.
10.11.1 Sage Therapeutics, Inc. Company Details
10.11.2 Sage Therapeutics, Inc. Business Overview
10.11.3 Sage Therapeutics, Inc. Fragile X Syndrome Introduction
10.11.4 Sage Therapeutics, Inc. Revenue in Fragile X Syndrome Business (2015-2020)
10.11.5 Sage Therapeutics, Inc. Recent Development
13.12 Zynerba Pharmaceuticals, Inc.
10.12.1 Zynerba Pharmaceuticals, Inc. Company Details
10.12.2 Zynerba Pharmaceuticals, Inc. Business Overview
10.12.3 Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Introduction
10.12.4 Zynerba Pharmaceuticals, Inc. Revenue in Fragile X Syndrome Business (2015-2020)
10.12.5 Zynerba Pharmaceuticals, Inc. Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Fragile X Syndrome Key Market Segments
Table 2. Key Players Covered: Ranking by Fragile X Syndrome Revenue
Table 3. Ranking of Global Top Fragile X Syndrome Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Fragile X Syndrome Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of ACT-01
Table 6. Key Players of AMO-01
Table 7. Key Players of ANAVEX-273
Table 8. Key Players of AUT-00206
Table 9. Key Players of Bryostatin-1
Table 10. Key Players of Cannabidiol
Table 11. Key Players of Others
Table 12. Global Fragile X Syndrome Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Fragile X Syndrome Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Fragile X Syndrome Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Fragile X Syndrome Market Share by Regions (2015-2020)
Table 16. Global Fragile X Syndrome Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Fragile X Syndrome Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Fragile X Syndrome Market Growth Strategy
Table 22. Main Points Interviewed from Key Fragile X Syndrome Players
Table 23. Global Fragile X Syndrome Revenue by Players (2015-2020) (Million US$)
Table 24. Global Fragile X Syndrome Market Share by Players (2015-2020)
Table 25. Global Top Fragile X Syndrome Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Fragile X Syndrome as of 2019)
Table 26. Global Fragile X Syndrome by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Fragile X Syndrome Product Solution and Service
Table 29. Date of Enter into Fragile X Syndrome Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Fragile X Syndrome Market Size by Type (2015-2020) (Million US$)
Table 32. Global Fragile X Syndrome Market Size Share by Type (2015-2020)
Table 33. Global Fragile X Syndrome Revenue Market Share by Type (2021-2026)
Table 34. Global Fragile X Syndrome Market Size Share by Application (2015-2020)
Table 35. Global Fragile X Syndrome Market Size by Application (2015-2020) (Million US$)
Table 36. Global Fragile X Syndrome Market Size Share by Application (2021-2026)
Table 37. North America Key Players Fragile X Syndrome Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Fragile X Syndrome Market Share (2019-2020)
Table 39. North America Fragile X Syndrome Market Size by Type (2015-2020) (Million US$)
Table 40. North America Fragile X Syndrome Market Share by Type (2015-2020)
Table 41. North America Fragile X Syndrome Market Size by Application (2015-2020) (Million US$)
Table 42. North America Fragile X Syndrome Market Share by Application (2015-2020)
Table 43. Europe Key Players Fragile X Syndrome Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Fragile X Syndrome Market Share (2019-2020)
Table 45. Europe Fragile X Syndrome Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Fragile X Syndrome Market Share by Type (2015-2020)
Table 47. Europe Fragile X Syndrome Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Fragile X Syndrome Market Share by Application (2015-2020)
Table 49. China Key Players Fragile X Syndrome Revenue (2019-2020) (Million US$)
Table 50. China Key Players Fragile X Syndrome Market Share (2019-2020)
Table 51. China Fragile X Syndrome Market Size by Type (2015-2020) (Million US$)
Table 52. China Fragile X Syndrome Market Share by Type (2015-2020)
Table 53. China Fragile X Syndrome Market Size by Application (2015-2020) (Million US$)
Table 54. China Fragile X Syndrome Market Share by Application (2015-2020)
Table 55. Japan Key Players Fragile X Syndrome Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Fragile X Syndrome Market Share (2019-2020)
Table 57. Japan Fragile X Syndrome Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Fragile X Syndrome Market Share by Type (2015-2020)
Table 59. Japan Fragile X Syndrome Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Fragile X Syndrome Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Fragile X Syndrome Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Fragile X Syndrome Market Share (2019-2020)
Table 63. Southeast Asia Fragile X Syndrome Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Fragile X Syndrome Market Share by Type (2015-2020)
Table 65. Southeast Asia Fragile X Syndrome Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Fragile X Syndrome Market Share by Application (2015-2020)
Table 67. India Key Players Fragile X Syndrome Revenue (2019-2020) (Million US$)
Table 68. India Key Players Fragile X Syndrome Market Share (2019-2020)
Table 69. India Fragile X Syndrome Market Size by Type (2015-2020) (Million US$)
Table 70. India Fragile X Syndrome Market Share by Type (2015-2020)
Table 71. India Fragile X Syndrome Market Size by Application (2015-2020) (Million US$)
Table 72. India Fragile X Syndrome Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Fragile X Syndrome Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Fragile X Syndrome Market Share (2019-2020)
Table 75. Central & South America Fragile X Syndrome Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Fragile X Syndrome Market Share by Type (2015-2020)
Table 77. Central & South America Fragile X Syndrome Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Fragile X Syndrome Market Share by Application (2015-2020)
Table 79. Aelis Farma SAS Company Details
Table 80. Aelis Farma SAS Business Overview
Table 81. Aelis Farma SAS Product
Table 82. Aelis Farma SAS Revenue in Fragile X Syndrome Business (2015-2020) (Million US$)
Table 83. Aelis Farma SAS Recent Development
Table 84. Alcobra Ltd Company Details
Table 85. Alcobra Ltd Business Overview
Table 86. Alcobra Ltd Product
Table 87. Alcobra Ltd Revenue in Fragile X Syndrome Business (2015-2020) (Million US$)
Table 88. Alcobra Ltd Recent Development
Table 89. AMO Pharma Limited Company Details
Table 90. AMO Pharma Limited Business Overview
Table 91. AMO Pharma Limited Product
Table 92. AMO Pharma Limited Revenue in Fragile X Syndrome Business (2015-2020) (Million US$)
Table 93. AMO Pharma Limited Recent Development
Table 94. Confluence Pharmaceuticals LLC Company Details
Table 95. Confluence Pharmaceuticals LLC Business Overview
Table 96. Confluence Pharmaceuticals LLC Product
Table 97. Confluence Pharmaceuticals LLC Revenue in Fragile X Syndrome Business (2015-2020) (Million US$)
Table 98. Confluence Pharmaceuticals LLC Recent Development
Table 99. Eli Lilly and Company Company Details
Table 100. Eli Lilly and Company Business Overview
Table 101. Eli Lilly and Company Product
Table 102. Eli Lilly and Company Revenue in Fragile X Syndrome Business (2015-2020) (Million US$)
Table 103. Eli Lilly and Company Recent Development
Table 104. F. Hoffmann-La Roche Ltd. Company Details
Table 105. F. Hoffmann-La Roche Ltd. Business Overview
Table 106. F. Hoffmann-La Roche Ltd. Product
Table 107. F. Hoffmann-La Roche Ltd. Revenue in Fragile X Syndrome Business (2015-2020) (Million US$)
Table 108. F. Hoffmann-La Roche Ltd. Recent Development
Table 109. Marinus Pharmaceuticals, Inc. Company Details
Table 110. Marinus Pharmaceuticals, Inc. Business Overview
Table 111. Marinus Pharmaceuticals, Inc. Product
Table 112. Marinus Pharmaceuticals, Inc. Revenue in Fragile X Syndrome Business (2015-2020) (Million US$)
Table 113. Marinus Pharmaceuticals, Inc. Recent Development
Table 114. MI.TO. Technology S.r.L. Business Overview
Table 115. MI.TO. Technology S.r.L. Product
Table 116. MI.TO. Technology S.r.L. Company Details
Table 117. MI.TO. Technology S.r.L. Revenue in Fragile X Syndrome Business (2015-2020) (Million US$)
Table 118. MI.TO. Technology S.r.L. Recent Development
Table 119. Neuren Pharmaceuticals Limited Company Details
Table 120. Neuren Pharmaceuticals Limited Business Overview
Table 121. Neuren Pharmaceuticals Limited Product
Table 122. Neuren Pharmaceuticals Limited Revenue in Fragile X Syndrome Business (2015-2020) (Million US$)
Table 123. Neuren Pharmaceuticals Limited Recent Development
Table 124. Ovid Therapeutics Inc. Company Details
Table 125. Ovid Therapeutics Inc. Business Overview
Table 126. Ovid Therapeutics Inc. Product
Table 127. Ovid Therapeutics Inc. Revenue in Fragile X Syndrome Business (2015-2020) (Million US$)
Table 128. Ovid Therapeutics Inc. Recent Development
Table 129. Sage Therapeutics, Inc. Company Details
Table 130. Sage Therapeutics, Inc. Business Overview
Table 131. Sage Therapeutics, Inc. Product
Table 132. Sage Therapeutics, Inc. Revenue in Fragile X Syndrome Business (2015-2020) (Million US$)
Table 133. Sage Therapeutics, Inc. Recent Development
Table 134. Zynerba Pharmaceuticals, Inc. Company Details
Table 135. Zynerba Pharmaceuticals, Inc. Business Overview
Table 136. Zynerba Pharmaceuticals, Inc. Product
Table 137. Zynerba Pharmaceuticals, Inc. Revenue in Fragile X Syndrome Business (2015-2020) (Million US$)
Table 138. Zynerba Pharmaceuticals, Inc. Recent Development
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Fragile X Syndrome Market Share by Type: 2020 VS 2026
Figure 2. ACT-01 Features
Figure 3. AMO-01 Features
Figure 4. ANAVEX-273 Features
Figure 5. AUT-00206 Features
Figure 6. Bryostatin-1 Features
Figure 7. Cannabidiol Features
Figure 8. Others Features
Figure 9. Global Fragile X Syndrome Market Share by Application: 2020 VS 2026
Figure 10. Clinic Case Studies
Figure 11. Hopital Case Studies
Figure 12. Research Center Case Studies
Figure 13. Fragile X Syndrome Report Years Considered
Figure 14. Global Fragile X Syndrome Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Fragile X Syndrome Market Share by Regions: 2020 VS 2026
Figure 16. Global Fragile X Syndrome Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Fragile X Syndrome Market Share by Players in 2019
Figure 19. Global Top Fragile X Syndrome Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Fragile X Syndrome as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Fragile X Syndrome Revenue in 2019
Figure 21. North America Fragile X Syndrome Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Fragile X Syndrome Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Fragile X Syndrome Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Fragile X Syndrome Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Fragile X Syndrome Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Fragile X Syndrome Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Fragile X Syndrome Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Bottom-up and Top-down Approaches for This Report
Figure 29. Data Triangulation
Figure 30. Key Executives Interviewed
レット症候群治療薬の世界市場（～2026年） Market Analysis and Insights: Global Rett Syndrome Therapeutics Market The global Rett Syndrome Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Rett Syndrome Therapeutics Scope and Market Size Rett Syndrom…- ドラベ症候群治療薬の世界市場（～2026年） Market Analysis and Insights: Global Dravet Syndrome Thereapeutics Market The global Dravet Syndrome Thereapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Dravet Syndrome Thereapeutics Scope and Market Size Dra…
- プラダーウィリー症候群治療薬の世界市場（～2026年） Market Analysis and Insights: Global Prader-Willi Syndrome Therapeutics Market The global Prader-Willi Syndrome Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Prader-Willi Syndrome Therapeutics Scope and …
- 間欠的発熱症候群の世界市場（～2026年） Periodic fever syndrome are a set of disorders characterized by recurrent episodes of systemic and organ-specific inflammation. The syndromes are diverse, but tend to cause episodes of fever, joint pains, skin rashes, abdominal pains and may lead to chronic complications such as amyloidosis. Market …
- 急性冠症候群（ACS）の世界市場（～2026年） Acute coronary syndrome (ACS) is a syndrome (set of signs and symptoms) due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies. The most common symptom is chest pain, often radiating to the left shoulder or angle of the jaw, cru…